Hypoxia-regulated transgene expression in experimental retinal and choroidal neovascularization

Gene Therapy

Volumn 10, Issue 12, 2003, Pages 1049-1054

  Bainbridge, J W B ^a   Mistry, A ^b   Binley, K ^c   De Alwis, M ^b   Thrasher, A J ^b   Naylor, S ^c   Ali, R R ^a,b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c OXFORD BIOMEDICA UK LTD   (United Kingdom)

Author keywords

Choroid; Gene transfer; Hypoxia; Neovascularization; Retina

Indexed keywords

ANGIOSTATIN; CIS ACTING ELEMENT; ERYTHROPOIETIN; GREEN FLUORESCENT PROTEIN; HYPOXIA INDUCIBLE FACTOR 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; PARVOVIRUS VECTOR; PIGMENT EPITHELIUM DERIVED FACTOR; RAPAMYCIN; TETRACYCLINE; UNCLASSIFIED DRUG; VIRUS VECTOR;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; GENE EXPRESSION; GENE TARGETING; HYPOXIA; HYPOXIA RESPONSIVE ELEMENT; ISCHEMIA; KINETICS; LASER; MOUSE; NONHUMAN; PRIORITY JOURNAL; REPORTER GENE; RETINA NEOVASCULARIZATION; SUBRETINAL NEOVASCULARIZATION; TRANSGENE; VIRAL GENE DELIVERY SYSTEM; VIRUS RECOMBINANT;

ANIMALS; ANOXIA; CELL HYPOXIA; CHOROIDAL NEOVASCULARIZATION; DEPENDOVIRUS; GENE EXPRESSION REGULATION; GENE TARGETING; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENES, REPORTER; GENETIC VECTORS; GREEN FLUORESCENT PROTEINS; LUMINESCENT PROTEINS; MICE; RESPONSE ELEMENTS; RETINAL NEOVASCULARIZATION; TRANSGENES;

ANIMALIA; MURINAE; PARVOVIRUS;

EID: 0037564988     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3301945     Document Type: Article

References (38)

1. Rahmani B et al. The cause-specific prevalence of visual impairment in an urban population. The Baltimore Eye Survey. Ophthalmology 1996; 103: 1721-1726.
2. Bressler NM, Bressler SB. Preventative ophthalmology. Age-related macular degeneration. Ophthalmology 1995; 102: 1206-1211.
3. Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology 1991; 98(Suppl 5): 766-785.
4. Laser photocoagulation of subfoveal recurrent neovascular lesions in age-related macular degeneration. Results of a randomized clinical trial. Macular Photocoagulation Study Group [see comments]. Arch Ophthalmol 1991; 109: 1232-1241.
5. Miller JW. Vascular endothelial growth factor and ocular neovascularization. Am J Pathol 1997; 151: 13-23.
6. Dawson DW et al. Pigment epithelium-derived factor: a potent inhibitor of angiogenesis. Science 1999; 285: 245-248.
7. Ali RR et al. Adeno-associated virus gene transfer to mouse retina. Hum Gene Ther 1998; 9: 81-86.
8. Bainbridge JW et al. In vivo gene transfer to the mouse eye using an HIV-based lentiviral vector; efficient long-term transduction of corneal endothelium and retinal pigment epithelium. Gene Ther 2001; 8: 1665-1668.
9. Bainbridge JW et al. Inhibition of retinal neovascularization by gene transfer of soluble VEGF receptor sFlt-1. Gene Ther 2002; 9: 320-326.
10. Lai YK et al. Potential long-term inhibition of ocular neovascularization by recombinant adeno-associated virus-mediated secretion gene therapy. Gene Ther 2002; 9: 804-813.
11. Mori K et al. Pigment epithelium-derived factor inhibits retinal and choroidal neovascularization. J Cell Physiol 2001; 188: 253-263.
12. Mori K et al. Regression of ocular neovascularization in response to increased expression of pigment epithelium-derived factor. Invest Ophthalmol Vis Sci 2002; 43: 2428-2434.
13. Lai CC et al. Suppression of choroidal neovascularization by adeno-associated virus vector expressing angiostatin. Invest Ophthalmol Vis Sci 2001; 42: 2401-2407.
14. Alon T et al. Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nat Med 1995; 1: 1024-1028.
15. Dejneka NS et al. Pharmacologically regulated gene expression in the retina following transduction with viral vectors. Gene Ther 2001; 8: 442-446.
16. McGee Sanftner LH et al. Recombinant AAV-mediated delivery of a tet-inducible reporter gene to the rat retina. Mol Ther 2001; 3(Part 1): 688-696.
17. Auricchio A et al. Pharmacological regulation of protein expression from adeno-associated viral vectors in the eye. Mol Ther 2002; 6: 238.
18. Boast K et al. Characterization of physiologically regulated vectors for the treatment of ischemic disease. Hum Gene Ther 1999; 10: 2197-2208.
19. Binley K et al. Long term reversal of chronic anemia using hypoxia-regulated erythropoietin gene therapy. Blood 2002; 100: 2406-2413.
20. Zhang X et al. High-titer recombinant adeno-associated virus production from replicating amplicons and herpes vectors deleted for glycoprotein H. Hum Gene Ther 1999; 10: 2527-2537.
21. Conway JE et al. High-titer recombinant adeno-associated virus production utilizing a recombinant herpes simplex virus type I vector expressing AAV-2 Rep and Cap. Gene Ther 1999; 6: 986-993.
22. Smith LE et al. Oxygen-induced retinopathy in the mouse. Invest Ophthalmol Vis Sci 1994; 35: 101-111.
23. Sarra GM et al. Kinetics of transgene expression in mouse retina following sub-retinal injection of recombinant adeno-associated virus. Vision Res 2002; 42: 541-549.
24. Tobe T et al. Targeted disruption of the FGF2 gene does not prevent choroidal neovascularization in a murine model. Am J Pathol 1998; 153: 1641-1646.
25. Ishibashi T et al. Expression of vascular endothelial growth factor in experimental choroidal neovascularization. Graefes Arch Clin Exp Ophthalmol 1997; 235: 159-167.
26. Semenza GL. Surviving ischaemia: adaptive responses mediated by hypoxia-inducible factor 1. J Clin Invest 2000; 106: 809-812.
27. Dachs GU et al. Targeting gene expression to hypoxic tumour cells. Nat Med 1997; 3: 515-520.
28. Binley K et al. An adenoviral vector regulated by hypoxia for the treatment of ischaemic disease and cancer. Gene Ther 1999; 6: 1721-1727.
29. Shibata T, Giaccia AJ, Brown JM. Hypoxia-inducible regulation of a prodrug-activating enzyme for tumour-specific gene therapy. Neoplasia 2002; 4: 40-48.
30. Tang Y, Jackson M, Qian K, Phillips MI. Hypoxia inducible double plasmid system for myocardial ischaemia gene therapy. Hypertension 2002; 39(Part 2): 695-698.
31. Phillips MI et al. Vigilant vector: heart-specific promoter in an adeno-associated virus vector for cardioprotection. Hypertension 2002; 39(Part 2): 651-655.
32. Pierce EA et al. Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization. Proc Natl Acad Sci USA 1995; 92: 905-909.
33. Kimura H et al. Hypoxia response element of the human vascular endothelial growth factor gene mediates transcriptional regulation by nitric oxide: control of hypoxia-inducible factor-1 activity by nitric oxide. Blood 2000; 95: 189-197.
34. Yi X et al. Vascular endothelial growth factor expression in choroidal neovascularization in rats. Graefes Arch Clin Exp Ophthalmol 1997; 235: 313-319.
35. Shen WY et al. Expression of cell adhesion molecules and vascular endothelial growth factor in experimental choroidal neovascularization in the rat. Br J Ophthalmol 1998; 82: 1063-1071.
36. Kwak N, Okamoto N, Wood JM, Campochiaro PA. VEGF is major stimulator in model of choroidal neovascularization. Invest Ophthalmol Vis Sci 2000; 41: 3158-3164.
37. Vinores SA et al. Upregulation of vascular endothelial growth factor in ischemic and non-ischemic human and experimental retinal disease. Histol Histopathol 1997; 12: 99-109.
38. Mousa SA, Lorelli W, Campochiaro PA. Role of hypoxia and extracellular matrix-integrin binding in the modulation of angiogenic growth factors secretion by retinal pigmented epithelial cells. J Cell Biochem 1999; 74: 135-143.